- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02903862
Health-eBrain Study (HeB)
Caregivers Virtual Health eBrain Study II
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study will track the mental status and cognition of caregivers with and without the Mindoula and DANA intervention and use subject feedback to aid in designing future interventions for caregivers.
This is a remotely administered, virtual study targeting dementia caregivers who are mild to moderately depressed. Screening calls for online administration of four surveys to determine inclusion in the study arms. These surveys will be taken on the Health-eBrain website, both at baseline/screening and throughout participation. All other participation will be completed on the participant's mobile phone, and all psychological and cognitive tests will be self-administered.
This study has a between-group design. Participants will be screened for eligibility and then randomized into each arm. The intervention arm will receive the Mindoula plus DANA intervention. The wait list control arm will take the psychological surveys at regular intervals then, after 12 weeks, be enrolled in the DANA-only observation group. The DANA-only group will take DANA and a usability questionnaire.
Type d'étude
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Maryland
-
Silver Spring, Maryland, États-Unis, 20910
- AnthroTronix Inc
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Females and males who regularly provide care for a person with Alzheimer's Disease
- Between the ages of 45-75
- Self-reported ability to speak and read English
- Providing care for at least a year
Participants in the Intervention and Waitlist Control Arms must meet the following additional inclusion criteria:
- Zarit Burden Inventory (ZBI) Score of 9+
- Overall M3 score of 33+
- M3 Depression score of 7+
- Female Only
- Minimum hours of caregiving a week must be equal to or greater than 20 hours
Exclusion Criteria:
- Anyone with a known cognitive diagnosis
- Anyone with color blindness
- Overall score of high risk on the M3 and/or high risk on the PTSD or Bipolar subsection of the M3
- Failure to meet all inclusion criteria per arm
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Intervention Arm
Participants will receive the intervention, Mindoula plus DANA, which involves working with a case manager via an app for 12 weeks.
The case manager will help the participant cope with the stresses of caregiving as well as remind them to use the DANA cognitive assessment app.
This arm will also take the study's psychological surveys.
|
The Mindoula intervention is a combination of case management and a messenger application.
Case managers monitor how the participant is doing and any needs and provide 24/7 support & assistance, including care coordination, treatment adherence, and matching the participant with providers and community resources.
Each participant will be given an intake questionnaire to establish goals and behavioral health history.
Participants will use the app and work with the case manager for 12 weeks.
DANA is an FDA-cleared neurocognitive assessment software administered on a smartphone or tablet to measure changes in cognitive efficiency.
DANA also includes Ecological Momentary Assessments to track mood, sleep, stress, and memory.
Intervention participants will take DANA weekly.
The Waitlist Control arm will take DANA weekly 12 weeks after enrollment.
|
|
Autre: Waitlist Control Arm
These participants will take psychological surveys and a usability questionnaire for the first 12 weeks of participation, then, for the 12 weeks following, take the psychological surveys along with DANA and a usability questionnaire.
|
DANA is an FDA-cleared neurocognitive assessment software administered on a smartphone or tablet to measure changes in cognitive efficiency.
DANA also includes Ecological Momentary Assessments to track mood, sleep, stress, and memory.
Intervention participants will take DANA weekly.
The Waitlist Control arm will take DANA weekly 12 weeks after enrollment.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Change from baseline M3 Behavioral Scale score over 12 weeks
Délai: At baseline, and 4, 8, and 12 weeks.
|
At baseline, and 4, 8, and 12 weeks.
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Change from baseline Zarit Burden Inventory score over 12 weeks
Délai: At baseline, and 4, 8, and 12 weeks.
|
At baseline, and 4, 8, and 12 weeks.
|
|
Change from baseline PROMIS Sleep Disturbance Short Form 8a score over 12 weeks
Délai: At baseline, and 4, 8, and 12 weeks.
|
At baseline, and 4, 8, and 12 weeks.
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Usability Questionnaire
Délai: At baseline, and 4, 8, and 12 weeks.
|
Survey on using DANA that will help the researchers better understand the development of technologies for this population
|
At baseline, and 4, 8, and 12 weeks.
|
|
Paired Associates Learning
Délai: At baseline and 12 weeks
|
The PAL assesses visual memory and new learning.
|
At baseline and 12 weeks
|
|
PERMA Profiler
Délai: At baseline and 12 weeks
|
This survey assesses five core element of psychological well-being and happiness - Positive emotions, Engagement, Relationships, Meaning, and Accomplishments - as well as subjective wellbeing and sense of loneliness.
|
At baseline and 12 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Corinna E Lathan, Ph.D, AnthroTronix, Inc.
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 091614A
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .